Your browser is no longer supported. Please, upgrade your browser.
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.59 Insider Own0.80% Shs Outstand159.63M Perf Week0.18%
Market Cap3.59B Forward P/E23.20 EPS next Y0.96 Insider Trans-15.91% Shs Float157.66M Perf Month18.96%
Income-94.60M PEG- EPS next Q0.12 Inst Own- Short Float7.02% Perf Quarter-3.71%
Sales1.04B P/S3.43 EPS this Y44.20% Inst Trans-0.05% Short Ratio8.37 Perf Half Y31.41%
Book/sh6.58 P/B3.40 EPS next Y90.32% ROA-5.00% Target Price22.11 Perf Year49.03%
Cash/sh3.37 P/C6.63 EPS next 5Y-14.10% ROE-8.90% 52W Range14.52 - 23.92 Perf YTD11.98%
Dividend- P/FCF75.34 EPS past 5Y14.40% ROI-9.40% 52W High-5.37% Beta0.98
Dividend %- Quick Ratio2.40 Sales past 5Y10.60% Gross Margin83.50% 52W Low55.89% ATR0.68
Employees2245 Current Ratio2.70 Sales Q/Q2.10% Oper. Margin-9.00% RSI (14)68.39 Volatility3.29% 3.33%
OptionableYes Debt/Eq0.28 EPS Q/Q42.60% Profit Margin-9.10% Rel Volume1.04 Prev Close22.34
ShortableYes LT Debt/Eq0.28 EarningsApr 28 BMO Payout- Avg Volume1.32M Price22.64
Recom3.00 SMA206.07% SMA5012.54% SMA20018.22% Volume653,267 Change1.32%
Oct-15-20Upgrade Mizuho Neutral → Buy $19 → $24
Jul-30-20Downgrade Goldman Neutral → Sell $19 → $15
Feb-14-20Reiterated H.C. Wainwright Neutral $26 → $25
Feb-14-20Downgrade JP Morgan Overweight → Neutral $21
Feb-14-20Downgrade BofA/Merrill Buy → Neutral $31 → $20
Feb-06-20Initiated Mizuho Neutral
Jan-31-20Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19Upgrade Morgan Stanley Underweight → Equal-Weight $30 → $20
Jul-15-19Upgrade Goldman Sell → Neutral
May-31-19Initiated H.C. Wainwright Neutral
May-01-19Downgrade Citigroup Buy → Neutral
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
May-07-21 04:11PM  
06:17AM  
May-05-21 04:00PM  
May-03-21 07:00AM  
Apr-30-21 07:00AM  
Apr-29-21 05:30PM  
10:52AM  
Apr-28-21 08:45AM  
07:05AM  
07:00AM  
06:15AM  
Apr-27-21 04:01PM  
07:00AM  
Apr-21-21 04:00PM  
Apr-20-21 04:01PM  
Apr-14-21 12:22PM  
Apr-08-21 08:49AM  
Apr-07-21 07:00AM  
Mar-31-21 01:31AM  
Mar-25-21 04:00PM  
07:00AM  
Mar-11-21 07:00AM  
Mar-08-21 09:20AM  
Mar-04-21 08:00AM  
Feb-18-21 04:00PM  
Feb-12-21 05:13PM  
Feb-11-21 06:30PM  
12:00PM  
08:35AM  
07:00AM  
06:15AM  
Feb-04-21 04:00PM  
Jan-30-21 01:08AM  
Jan-28-21 04:55PM  
Jan-25-21 09:28AM  
Jan-22-21 09:02AM  
Jan-21-21 12:57PM  
12:16PM  
07:14AM  
Jan-15-21 09:11AM  
Jan-14-21 10:46AM  
07:00AM  
Jan-13-21 02:17PM  
Jan-12-21 10:27AM  
10:04AM  
Jan-11-21 08:46AM  
Jan-08-21 09:57AM  
Jan-07-21 10:52AM  
10:51AM  
08:45AM  
Jan-06-21 04:00PM  
11:13AM  
09:24AM  
07:00AM  
Dec-29-20 10:23AM  
08:09AM  
07:00AM  
Dec-28-20 10:00AM  
Dec-24-20 11:25PM  
09:14AM  
Dec-22-20 12:00PM  
Dec-11-20 08:34AM  
Dec-10-20 02:58PM  
07:00AM  
Nov-23-20 11:35PM  
Nov-18-20 12:24PM  
11:13AM  
10:49AM  
Nov-17-20 08:31AM  
07:00AM  
Nov-09-20 08:01AM  
Nov-03-20 04:00PM  
Oct-30-20 06:00PM  
03:54PM  
Oct-29-20 10:24AM  
08:45AM  
07:00AM  
06:00AM  
Oct-27-20 10:38AM  
10:31AM  
Oct-26-20 09:22AM  
Oct-22-20 04:00PM  
11:19AM  
Oct-21-20 12:33PM  
Oct-19-20 06:59AM  
Oct-12-20 04:12PM  
10:35AM  
Oct-09-20 05:11PM  
07:05AM  
Oct-07-20 10:14AM  
Sep-28-20 08:53PM  
Sep-25-20 11:40AM  
Sep-18-20 06:30AM  
Sep-14-20 12:06PM  
07:00AM  
Sep-13-20 08:59AM  
Sep-09-20 04:00PM  
11:40AM  
Sep-08-20 07:00AM  
Aug-28-20 11:31AM  
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 07Option Exercise18.1119,477352,631236,258May 07 04:48 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 07Sale22.1019,477430,522216,781May 07 04:48 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 06Option Exercise18.11100,0001,810,500892,040May 07 04:47 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 06Sale21.79100,0002,179,410792,040May 07 04:47 PM
Jackson Blair CurtisEVP, Chief Operating OfficerMay 03Option Exercise18.1134,503624,677102,657May 04 04:17 PM
Jackson Blair CurtisEVP, Chief Operating OfficerMay 03Sale22.1834,503765,15668,154May 04 04:17 PM
Brown Iain MichaelSVP, Chief Financial OfficerApr 19Option Exercise18.1134,792629,90983,154Apr 20 07:20 PM
DIXON WENDY LDirectorApr 19Option Exercise14.6025,000365,00061,600Apr 20 07:22 PM
DIXON WENDY LDirectorApr 19Sale20.0025,000500,12036,600Apr 20 07:22 PM
Brown Iain MichaelSVP, Chief Financial OfficerApr 19Sale20.0034,792695,76048,362Apr 20 07:20 PM
Brown Iain MichaelSVP, Chief Financial OfficerApr 16Option Exercise18.112083,76648,570Apr 20 07:20 PM
Brown Iain MichaelSVP, Chief Financial OfficerApr 16Sale19.992084,15848,362Apr 20 07:20 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerApr 15Sale19.7228,920570,2880Apr 16 04:35 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 21Option Exercise0.0032,4000806,426Feb 23 09:37 PM
Jackson Blair CurtisEVP, Chief Operating OfficerFeb 21Option Exercise0.004,800069,566Feb 23 09:29 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 21Option Exercise0.006,875030,942Feb 23 09:25 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 21Option Exercise0.006,875076,619Feb 23 09:25 PM
Brown Iain MichaelSVP, Chief Financial OfficerFeb 21Option Exercise0.004,800049,774Feb 23 09:24 PM
Nichols Christian ToddSVP, Chief Commercial OfficerFeb 20Option Exercise0.003,82406,295Feb 23 09:55 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 20Option Exercise0.0011,1780219,368Feb 23 09:36 PM
Jackson Blair CurtisEVP, Chief Operating OfficerFeb 20Option Exercise0.004,589066,140Feb 23 09:29 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 20Option Exercise0.0010,095027,131Feb 23 09:25 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 20Option Exercise0.007,036071,805Feb 23 09:25 PM
Brown Iain MichaelSVP, Chief Financial OfficerFeb 20Option Exercise0.004,589046,352Feb 23 09:24 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500777,895Feb 18 07:28 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000212,042Feb 18 07:27 PM
Jackson Blair CurtisEVP, Chief Operating OfficerFeb 17Option Exercise0.002,250062,332Feb 18 07:26 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500065,637Feb 18 07:24 PM
Brown Iain MichaelSVP, Chief Financial OfficerFeb 17Option Exercise0.002,500042,631Feb 18 07:23 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 16Option Exercise0.0018,1250777,219Feb 18 07:28 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 16Option Exercise0.003,3750210,720Feb 18 07:27 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerFeb 16Option Exercise0.003,375018,208Feb 18 07:25 PM
Jackson Blair CurtisEVP, Chief Operating OfficerFeb 16Option Exercise0.002,375060,907Feb 18 07:26 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 16Option Exercise0.003,375064,309Feb 18 07:24 PM
Brown Iain MichaelSVP, Chief Financial OfficerFeb 16Option Exercise0.002,375040,956Feb 18 07:23 PM
DIXON WENDY LDirectorJan 13Option Exercise12.6235,000441,70036,600Jan 15 04:38 PM
MITCHELL PAUL JDirectorOct 01Option Exercise14.9220,000298,40027,000Oct 02 04:40 PM
MITCHELL PAUL JDirectorOct 01Sale16.6120,000332,2627,000Oct 02 04:40 PM
ANSTICE DAVID WDirectorSep 28Option Exercise14.9220,000298,40086,213Oct 05 05:46 PM
ANSTICE DAVID WDirectorSep 28Sale16.7917,832299,31068,381Oct 05 05:46 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Jul 14Option Exercise18.115,52399,994207,345Jul 15 04:55 PM
Hopkinson Craig C.EVP R&D, Chief Medical OfficerJun 07Option Exercise0.001,250015,201Jun 08 04:21 PM
Nichols Christian ToddSVP, Chief Commercial OfficerJun 05Option Exercise0.003,50003,500Jun 08 04:19 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 14Option Exercise11.7475,000880,500834,094May 14 05:00 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMay 14Option Exercise11.7421,983258,08091,828May 14 04:58 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 14Sale15.0075,0001,125,232759,094May 14 05:00 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 13Option Exercise11.746,25073,37544,831May 14 04:55 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.May 13Sale15.396,25096,19338,581May 14 04:55 PM